Gamida Cell Ltd.

202 articles about Gamida Cell Ltd.

• Gamida Cell to Present at Upcoming Investor Conferences

  3/3/2021

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced today that company management will participate in two upcoming investor conferences in March: H.C. Wainwright Global Life Sciences Conference, March 10, 2021. Company presentation will be available for on-demand viewing at 7:00 a.m. ET on Tuesday, March 9, 2021.

• Gamida Cell Announces the Date of Its Full Year 2020 Financial Results and Webcast

  3/2/2021

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Tuesday, March 9, 2021, at 8:30 a.m. ET to review its full year 2020 financial results and provide an update on the company.

• Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

  3/1/2021

  Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47 th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

• Gamida Cell Announces $75 Million Financing with Highbridge Capital Management

  2/16/2021

  Pro forma Cash Expected to Fund Manufacturing, Regulatory and Commercial Readiness Preparations for Omidubicel and the Advancement of GDA-201 Clinical Development

• Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 2021 TCT Meetings of ASTCT and CIBMTR

  2/9/2021

  — Omidubicel represents a potentially transformative cell therapy treatment option for patients in need of a bone marrow transplant — —Newly presented data support clinical benefit demonstrated by primary and secondary endpoints— —Company anticipates BLA submission in second half of 2021—

• Gamida Cell to Present Full Data from Phase 3 Study of Omidubicel at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR

  1/11/2021

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that the full results of the Phase 3 clinical trial of omidubicel will be presented for the first time at the TCT Meetings, the Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy (ASTCT) and Center for International Blo

• Gamida Cell Announces Closing of $75 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

  12/21/2020

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that its previously announced public offering closed on December 21, 2020. The total number of ordinary shares sold by the Company in the offering was 9,343,750, inclusive of the full exercise of the underwriters’ option to purchase up to an additional 1,218,750 shares, at the pu

• Gamida Cell Announces Pricing of $65 Million Public Offering of Ordinary Shares

  12/17/2020

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the pricing of a follow-on public offering of 8,125,000 ordinary shares at a public offering price of $8.00 per share for aggregate gross proceeds of $65.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Gamida Cell h

• Gamida Cell to Host Virtual Pipeline Deep Dive

  12/2/2020

    - Focused on omidubicel, an advanced cell therapy, including a review of Phase 3 clinical data, and GDA-201, a natural killer cell therapy – - Event to feature an omidubicel patient’s perspective - - Live webcast on December 9, 2020 at 8:00 a.m. ET -

• Gamida Cell Reports Third Quarter 2020 Financial Results and Provides Company Update

  11/10/2020

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today reported financial results for the quarter ended September 30, 2020.

• Gamida Cell Announces Data to Be Presented at 62nd ASH Annual Virtual Meeting

  11/4/2020

  Nov. 4, 2020 15:30 UTC Gamida Cell Announces Data to Be Presented at 62 nd ASH Annual Virtual Meeting – Updated data from Phase 1 Study of GDA-201 to be presented during an oral session – – New data on omidubicel in patients with severe aplastic anemia will also be presented –

• Gamida Cell to Present at H.C. Wainwright 6th Annual Israel Conference

  11/4/2020

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Ph. D., chief executive officer of Gamida Cell, will present at the H.C. Wainwright 6 th Annual Israel Conference on Thursday, November 12, 2020 at 11:00 a.m. ET. A live webcast of the pre

• Gamida Cell and Be The Match BioTherapies® Expand Strategic Collaboration

  10/13/2020

  Gamida Cell and Be The Match BioTherapies ® Expand Strategic Collaboration – Organizations to work together to integrate Be The Match BioTherapies’ existing cell therapy infrastructure to manage the supply chain for potential commercialization of omidubicel –

• Gamida Cell Announces Positive Topline Data on Secondary Endpoints from Phase 3 Clinical Study of Omidubicel in Patients with Hematologic Malignancies

  10/6/2020

  Gamida Cell Ltd., an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced that the Phase 3 study of omidubicel, an investigational advanced cell therapy in development as a potential life-saving treatment option for patients in need of bone marrow transplant, met all three of its secondary endpoints.

• Gamida Cell to Participate in Upcoming Investor Conferences

  9/8/2020

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced that company management will participate in three upcoming virtual investor conferences in September: H.C. Wainwright 22 nd Annual Global Investment Conference Date: Monday, September 14, 2020 Presentation: 11:00 a.m. ET Cantor Virtual Global Healthcare Confer

• Gamida Cell Announces Two-Part Virtual Miniseries Focused on Omidubicel to Take Place in September

  9/3/2020

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that it will host a two-part virtual miniseries in September focused on key topics related to omidubicel , an advanced cell therapy in Phase 3 clinical development as a potentially life-saving treatment option for patients in need of a bone marrow transplant. The webcasts will take

• Gamida Cell to Provide Webcast of Its Annual Meeting of Stockholders

  8/17/2020

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that it will webcast its Annual Meeting of Stockholders on Thursday, September 10, 2020, at 10:00 a.m. ET (5:00 p.m. Israel time) at 12 Leshem Street, Kiryat Gat, 8258412, Israel. During the meeting, Julian Adams, Ph.D., Gamida Cell’s chief executive officer, will present an overview o

• Gamida Cell Announces the Date of Its Second Quarter 2020 Financial Results and Webcast

  8/4/2020

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Tuesday, August 11, 2020, at 8:30 a.m. ET to review its second quarter 2020 financial results and provide an update on the company. The webcast will be available on the “Investors & Media” section of the Gam

• Gamida Cell Announces Appointment of Michele Korfin as Chief Operating and Chief Commercial Officer

  7/21/2020

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced the appointment of Michele Korfin as chief operating and chief commercial officer. Ms. Korfin brings over 20 years of experience in oncology, focused on business operations and commercialization of novel therapies. In this role, she will have oversight of manufacturing and comm

• Gamida Cell Announces Appointment of David Fox to Its Board of Directors

  7/7/2020

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced that David Fox has been appointed to Gamida Cell’s board of directors as an independent member. Mr. Fox brings significant leadership, company-building and business development experience to Gamida Cell’s board of directors as the company advances its clinical development candid